ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.07), Zacks reports.
ProMIS Neurosciences Stock Performance
Shares of NASDAQ PMN opened at $0.56 on Monday. The stock has a market cap of $18.44 million, a PE ratio of -5.75 and a beta of 0.02. The business has a fifty day moving average of $0.65 and a two-hundred day moving average of $0.84. ProMIS Neurosciences has a 52-week low of $0.47 and a 52-week high of $2.37.
Analyst Ratings Changes
A number of research firms have commented on PMN. Maxim Group initiated coverage on shares of ProMIS Neurosciences in a research note on Monday. They set a “buy” rating and a $3.00 price objective for the company. Guggenheim reissued a “buy” rating and issued a $6.00 price target on shares of ProMIS Neurosciences in a research report on Tuesday, April 1st.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Further Reading
- Five stocks we like better than ProMIS Neurosciences
- What Are Dividend Achievers? An Introduction
- Tech Bears Should Jump on These 3 Inverse ETFs
- What Are Dividend Challengers?
- 5 Reasons the Rebound in Microchip Technology Stock Is Real
- Election Stocks: How Elections Affect the Stock Market
- Rocket Lab: Earnings Miss But Neutron Momentum Holds
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
